The cost of healthcare should trend down as more and more drugs enter the public domain and generics become available. However this clearly isn't happening.
It is also interesting when does the social benefit of a drug outweigh the benefit of creating an 'incentive' for drug companies. If GLP-1 drugs are worthy of the hype, we're basically talking about 20 years of unneeded suffering and trillions of dollars of avoidable damage to society all to give a drug company a limited monopoloy. At a certain point the US should just eminent domain the patent, give them some reasonable compensation, and make the drug broadly available to all Americans similar to COVID vaccines.
replies(2):